SLU-PP-332 for Energy: What the Evidence Shows
What human and animal studies show about SLU-PP-332 for energy, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Animal
- Human studies
- None found
- with an outcome for energy, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 3
- with an outcome for energy, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 3
- with an outcome for energy
Evidence for energy
Each row is an outcome related to energy from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Energy expenditure and fatty acid oxidation | In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism. | Animal · mouse (not a human result) | The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 |
| Exercise endurance | In mice, SLU-PP-332 increased type IIa oxidative skeletal muscle fibers and enhanced exercise endurance. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Mitochondrial function in muscle cells | SLU-PP-332 increased mitochondrial function and cellular respiration in a skeletal muscle cell line. | Animal · mouse (plus a skeletal muscle cell line) (not a human result) | ACS chemical biology 2023, PMID 36988910 |
| Aging kidney | An 8-week pan-ERR agonist treatment reversed age-related albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in aged mice. | Animal · mouse (not a human result) | The American journal of pathology 2023, PMID 37717940 |
SLU-PP-332 and energy are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Fatigue defined
MedlinePlus defines fatigue as weariness, tiredness or lack of energy.[4]
What SLU-PP-332 studies measured that is closest to energy
In obese mice, energy expenditure and fatty acid oxidation rose; this is a metabolic measurement and not a feeling of energy.[1]
In a skeletal muscle cell line, the compound increased mitochondrial function and respiration; this is a cell result.[2]
In aged mice, the compound reversed mitochondrial dysfunction in the kidney.[3]
All 3 cached studies for this page are in mice or cell lines, 0 are in people, and none asked about tiredness or energy levels.
Calculated from cached studies 3; in animals or cells 3; in humans 0; sources 37739806, 36988910, 37717940. Formula: humans = cachedStudies - inAnimalsOrCells = 3 - 3
Other peptides people research for energy
All peptides for energy, comparedCommon questions
Does SLU-PP-332 help with energy?
The strongest study we summarise for energy is animal evidence, across 3 studies with an outcome for energy. That is not proof it works in people.
Is SLU-PP-332 approved for energy?
No. SLU-PP-332 is not FDA approved for any use, including energy.
What is the best peptide for energy?
There is no single answer. Our energy overview compares each candidate by evidence grade and legal status rather than by popularity.
Does SLU-PP-332 give you energy?
No human study measured it; the mouse studies measured expenditure and endurance.[2]
More on SLU-PP-332
Sources
- 1A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 2Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.ACS chemical biology · 2023PMID 36988910Accessed 2 Oct 2026
- 3Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.The American journal of pathology · 2023PMID 37717940Accessed 2 Oct 2026
- 4Official web pageOfficial web page · web page
Found an error? Report a correction.